Regulatory Terms Starting With A

Abbreviated New Drug Application (ANDA)

An application for FDA approval of a generic drug product that references an already-approved drug.

Accelerated Approval (AA)

An FDA pathway allowing earlier approval based on surrogate or intermediate endpoints for serious conditions.

Accelerated Stability

Accelerated Stability is used to prevent quality failures and strengthen manufacturing control strategy.

Active Pharmaceutical Ingredient (API)

The substance in a pharmaceutical drug that is biologically active and produces the intended therapeutic effect.

Adaptive TRIAL DESIGN

Adaptive TRIAL DESIGN is an important device-regulatory concept for pathway selection, evidence strategy, and compliance.

Adverse Event (AE)

Any untoward medical occurrence in a patient or clinical trial subject administered a pharmaceutical product.

Aggregate Reporting

Aggregate Reporting is a recurring concept across regulatory planning, compliance operations, and global submissions.

Analytical METHOD Validation

Analytical METHOD Validation is foundational for process control, product quality, and inspection-readiness in manufacturing.

ANDS (ANDS)

ANDS helps teams standardize terminology and improve decision traceability.

ANNEX 11

ANNEX 11 supports cross-functional regulatory execution across quality, clinical, and safety teams.

Annual Report (AR)

A yearly report submitted to FDA summarizing changes and updates to an approved drug application.

Approval LETTER

Approval LETTER shapes how sponsors structure filings, amendments, and authority responses.

AUDIT TRAIL

AUDIT TRAIL is used to support defensible premarket and postmarket device decisions.